Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Ireland News News

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Ireland Latest News,Ireland Headlines
  • 📰 Nature
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 68%

Nature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

and is provided in this format here as a response to the exceptional public-health crisis. This accepted manuscript will continue through the processes of copy editing and formatting to publication of a finalized version of record on nature.com. Please note there may be errors present in this version, which may affect the content, and all legal disclaimers apply.

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in the receptor-binding domain , thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics. Here, we show that the Omicron RBD binds to human ACE2 with enhanced affinity, relative to the Wuhan-Hu-1 RBD, and binds to mouse ACE2.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Nature /  🏆 64. in US

Ireland Latest News, Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Read more »

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature research paper: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Read more »

A new tool to probe SARS-CoV-2 variantsA new tool to probe SARS-CoV-2 variantsVirus-like particles offer a new way to investigate genetic variation in SARSCoV2. Learn more in a new SciencePerspective:
Read more »

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the SARSCoV2 main protease, a key viral target. In a phase I clinical trial, it achieved concentrations expected to inhibit the virus based on in vitro studies. pfizer
Read more »

SARS-CoV-2 infection in free-ranging white-tailed deer - NatureNature - <ArticleTitle Language="En" xml:lang="en">SARS-CoV-2 infection in free-ranging white-tailed deer</ArticleTitle>
Read more »

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Read more »



Render Time: 2025-03-12 19:16:03